Labor Induction versus Expectant Management in Low-Risk Nulliparous Women
Source: View publication →
Among low-risk nulliparous women, elective labor induction at 39 weeks did not significantly improve a composite of adverse perinatal outcomes but did significantly reduce the rate of cesarean delivery and hypertensive disorders of pregnancy compared to expectant management.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ARRIVE trial was a paradigm-shifting study that reversed the long-held obstetric dogma that elective induction inherently increases the risk of cesarean section in nulliparous women. Its robust findings prompted major professional societies, including ACOG and SMFM, to endorse offering elective induction at 39 weeks as a safe and reasonable clinical option through shared decision-making.
Historical Context
Historically, elective induction in nulliparous women was highly discouraged based on older observational data that associated it with increased rates of cesarean delivery. However, these earlier studies were heavily flawed by comparing elective induction at 39 weeks to spontaneous labor at 39 weeks, rather than the true clinical alternative of expectant management (which carries the real-world risks of post-term complications, macrosomia, and later indicated inductions). The ARRIVE trial was definitively designed to correct this methodological flaw by utilizing a properly randomized expectant management control group.
Guided Discussion
High-yield insights from every perspective
In the ARRIVE trial, elective induction at 39 weeks was associated with a lower rate of hypertensive disorders of pregnancy. Based on the pathophysiology of preeclampsia and gestational hypertension, why is delivery at 39 weeks protective compared to expectant management?
Key Response
Preeclampsia and gestational hypertension are driven by placental dysfunction and the release of anti-angiogenic factors that accumulate over time. The placenta is the source of the disease; therefore, delivering the placenta at 39 weeks halts the progressive endothelial damage, preventing the clinical onset of hypertensive disorders that would otherwise develop during the expectant management period.
When counseling a low-risk nulliparous patient at 38 weeks about elective induction versus expectant management, how do you explain the impact on the risk of cesarean delivery based on the ARRIVE trial, and what Bishop score considerations should be factored into the decision?
Key Response
The ARRIVE trial showed a statistically significant decrease in the cesarean delivery rate for the induction group (18.6% vs 22.2%) regardless of the initial Bishop score. Residents must translate this to patients by explaining that induction at 39 weeks actually decreases the risk of needing a C-section compared to waiting, challenging the old dogma that inducing an unripe cervix increases C-section risk.
The primary outcome of the ARRIVE trial was a composite of perinatal mortality and severe neonatal morbidity. Despite a reduction in the relative risk, it did not reach statistical significance (p=0.08). As an MFM fellow, how do you interpret the composition of this primary outcome, its statistical power given the baseline event rate, and the implications for neonatal safety?
Key Response
The primary composite outcome had a lower than expected baseline event rate in this low-risk population, meaning the trial was ultimately underpowered to detect a statistically significant difference. However, the point estimate favored induction, and fellows should recognize that the data strongly supports that 39-week induction does not cause neonatal harm (like increased respiratory distress) compared to expectant management.
Adopting the ARRIVE trial findings broadly means offering 39-week induction to all low-risk nulliparous women. From a labor and delivery unit leadership perspective, what are the logistical, resource, and throughput implications of shifting to this practice model?
Key Response
While medically beneficial in reducing C-sections, 39-week inductions, particularly with unfavorable cervices, significantly increase the time patients spend occupying L&D beds compared to spontaneous labor. Attendings must weigh the clinical benefits against operational strain on nursing staff, bed availability, and hospital costs, making unit throughput a critical barrier to universal implementation.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Only about 27% of eligible women consented to participate in the ARRIVE trial. How does this low participation rate introduce volunteer bias, and what methodological concerns does this raise regarding the external validity and generalizability of the absolute risk reductions observed for cesarean delivery?
Key Response
A low consent rate suggests the study population may not perfectly represent the general population of low-risk nulliparous women. Women who agree to participate in a randomized trial about labor induction might differ in unmeasured ways (e.g., pain tolerance, birth preferences, socioeconomic status) from those who decline, potentially skewing the baseline cesarean rate or the effectiveness of the intervention in a broader, unselected population.
Due to the nature of the intervention, the ARRIVE trial could not be blinded for patients or providers. As a reviewer evaluating this trial, how might the lack of provider blinding have influenced the secondary outcome of cesarean delivery rates, particularly regarding the threshold for diagnosing failure to progress?
Key Response
Providers knew which arm the patients were in. For a patient in the expectant management group, providers might have had different thresholds for patience before calling a C-section compared to an elective 39-week induction where strict, standardized protocols for cervical ripening and oxytocin administration were emphasized, potentially introducing an ascertainment bias that favored the induction group.
Following the ARRIVE trial, ACOG released a Practice Advisory stating that it is 'reasonable to offer' elective induction of labor at 39 weeks to low-risk nulliparous women. Why did ACOG choose this wording rather than making it a universal recommendation, and what shared decision-making elements must be documented according to these guidelines?
Key Response
ACOG recognized the clinical benefits (reduced C-sections and hypertensive disorders) but stopped short of a universal mandate due to patient autonomy, varying birth preferences, and systemic resource limitations. The 'reasonable to offer' language requires shared decision-making where the clinician discusses the modest absolute risk reduction in C-section, lack of significant neonatal benefit, longer duration of labor, and ensures firm gestational age dating before proceeding.
Clinical Landscape
Noteworthy Related Trials
Hannah Post-term Trial
Tested
Induction of labor at 41 weeks
Population
Women with uncomplicated pregnancies at 41 or more weeks of gestation
Comparator
Expectant management with serial fetal monitoring
Endpoint
Perinatal mortality and neonatal morbidity
HYPITAT Trial
Tested
Induction of labor
Population
Women with gestational hypertension or mild pre-eclampsia at 36-41 weeks
Comparator
Expectant management
Endpoint
Composite of poor maternal outcome
SWEPIS Trial
Tested
Induction of labor at 41 weeks
Population
Low-risk women with uncomplicated pregnancies at 41 weeks
Comparator
Expectant management until 42 weeks
Endpoint
Composite perinatal morbidity and mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis